Dizal’s Golidocitinib Gains the NMPA’s Approval to Treat Peripheral T-Cell Lymphoma
Shots:
- The NMPA has granted approval to golidocitinib (JAK1 selective inhibitor) for treating r/r peripheral T-cell lymphoma (PTCL) adults whose disease progressed after at least 1 previous systemic therapy
- The approval was supported by a JACKPOT8 Part B (JACKPOT8B) trial assessing the safety & efficacy of golidocitinib monotx. to treat r/r PTCL
- The study, as of Aug 2023, depicted an ORR of 44.3% with CRR of 23.9% and mDoR of 20.7mos. with 53.8% of them still responding. Full data was highlighted at ASH 2023 & published in The Lancet Oncology
Ref: Dizal | Image: Dizal
Related News:- Dizal's Sunvozertinib Receives the NMPA’s Approval for Non-Small Cell Lung Cancer with EGFR Exon20ins Mutations
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.